Evidence map›Paper›PMID 36452219›Full record

ArticleFrontiers in pharmacology2022

Novel recombinant protein flagellin A N/C attenuates experimental autoimmune encephalomyelitis by suppressing the ROS/NF-κB/NLRP3 signaling pathway.

Li Li, Shihua Deng, Mingquan Liu, Min Yang, Jin Li, Teng Liu, Ting Zhang, Yangyang Zhao, Miao He, Dongming Wu and 1 more

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Li LiClinical Medical College and the First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
Shihua DengClinical Medical College and the First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
Mingquan LiuClinical Medical College and the First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
Min YangClinical Medical College and the First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
Jin LiClinical Medical College and the First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
Teng LiuClinical Medical College and the First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
Ting ZhangClinical Medical College and the First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
Yangyang ZhaoClinical Medical College and the First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
Miao HeClinical Medical College and the First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
Dongming WuClinical Medical College and the First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
Ying XuClinical Medical College and the First Affiliated Hospital of Chengdu Medical College, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease characterized by demyelination and neurodegeneration, for which traditional treatment offers limited relief. Microglial/macrophage modulation plays a critical role in the pathogenesis of MS. Oxygen free radical accumulation can induce axonal and nerve cell damage, and further promote MS development. We created a new recombinant protein based on flagellin from

Indexed as

experimental autoimmune encephalomyelitisFlaAN/Cpyroptosisreactive oxygen speciesROS/NF-κB/NLRP3 pathway

Identifiers

PMID36452219
PMCPMC9702353

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.